Loading…
Combined reduced-antigen-content diphtheria–tetanus–acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults
Many countries recommend diphtheria, tetanus and/or poliomyelitis boosters in adolescents or adults and the need for pertussis booster vaccination beyond childhood is increasingly recognized. A new combined reduced-antigen-content dTpa-IPV vaccine provides booster vaccination against all four diseas...
Saved in:
| Published in: | Vaccine 2005-05, Vol.23 (28), p.3657-3667 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c452t-4fb1841d4f2cf0bb08621f8643eb0bbad6458ce377f8427fd03735cafd2849213 |
|---|---|
| cites | |
| container_end_page | 3667 |
| container_issue | 28 |
| container_start_page | 3657 |
| container_title | Vaccine |
| container_volume | 23 |
| creator | Grimprel, Emmanuel von Sonnenburg, Frank Sänger, Roland Abitbol, Veronique Wolter, Joanne M. Schuerman, Lode M. |
| description | Many countries recommend diphtheria, tetanus and/or poliomyelitis boosters in adolescents or adults and the need for pertussis booster vaccination beyond childhood is increasingly recognized. A new combined reduced-antigen-content dTpa-IPV vaccine provides booster vaccination against all four diseases in one single injection. The immunogenicity and safety of the dTpa-IPV vaccine was compared to that of licensed dTpa
+
IPV or Td-IPV vaccines in 806 adolescents >14 years of age and adults with a heterogeneous vaccination history. The dTpa-IPV vaccine was immunogenic and well tolerated. No clinically significant differences were observed between groups. Anti-tetanus antibody kinetics indicated that each of the vaccines could be used for tetanus prophylaxis in acute wound management. For all vaccines, the lowest post-vaccination antibody concentrations were observed in subjects >40 years of age, those seronegative prior to vaccination and those subjects whose last vaccination was ≥20 years ago. In conclusion, dTpa-IPV vaccination of subjects over 14 years of age was as immunogenic and well tolerated as the licensed dTpa
+
IPV or Td-IPV vaccines. Vaccination coverage of adults is poor and the use of combined vaccines such as dTpa-IPV during vaccination visits, or for wound management, maximizes opportunities for boosting in these difficult to reach age groups. |
| doi_str_mv | 10.1016/j.vaccine.2005.02.013 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67819027</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X05002847</els_id><sourcerecordid>3379187191</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-4fb1841d4f2cf0bb08621f8643eb0bbad6458ce377f8427fd03735cafd2849213</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhhtR3NnVn6AExEUPPearO5mTyODHwoIeVvEW0knFzdCT9CbpBW-evfoP_SVmmIYFLwsFqSJPvVTV2zTPCF4TTPo3u_WtNsYHWFOMuzWma0zYg2ZFpGAt7Yh82Kww7XnLCf5-0pzmvMMVZGTzuDkhnZS0o_2q-b2N-6GqWJTAzgZsq0PxPyC0JoYCoSDrp-tyDcnrv7_-FCg6zLlm2sA4zqNOaIJU5px9RjpYNMXRR7TMhl7Zq0m3F1--vUYuJjTEmAuk5VsXHwOKDmk7jyU_aR45PWZ4urxnzdcP76-2n9rLzx8vtu8uW8M7WlruBiI5sdxR4_AwYNlT4mTPGQy11LbnnTTAhHCSU-EsZoJ1RjtLJd9Qws6a86PulOLNDLmovc-HbXSAOGfVC0k2mIp7QSIo6xmXFXzxH7iLcwp1CUU6LjCTNSrVHSmTYs4JnJqS3-v0UxGsDp6qnVrupg6eKkxV9bT2PV_U52EP9q5rMbECLxdAZ6NHl3QwPt9xgvRMigP39shBve6th6Sy8RCq6T6BKcpGf88o_wCANcWx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1547038038</pqid></control><display><type>article</type><title>Combined reduced-antigen-content diphtheria–tetanus–acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults</title><source>ScienceDirect Journals</source><creator>Grimprel, Emmanuel ; von Sonnenburg, Frank ; Sänger, Roland ; Abitbol, Veronique ; Wolter, Joanne M. ; Schuerman, Lode M.</creator><creatorcontrib>Grimprel, Emmanuel ; von Sonnenburg, Frank ; Sänger, Roland ; Abitbol, Veronique ; Wolter, Joanne M. ; Schuerman, Lode M.</creatorcontrib><description>Many countries recommend diphtheria, tetanus and/or poliomyelitis boosters in adolescents or adults and the need for pertussis booster vaccination beyond childhood is increasingly recognized. A new combined reduced-antigen-content dTpa-IPV vaccine provides booster vaccination against all four diseases in one single injection. The immunogenicity and safety of the dTpa-IPV vaccine was compared to that of licensed dTpa
+
IPV or Td-IPV vaccines in 806 adolescents >14 years of age and adults with a heterogeneous vaccination history. The dTpa-IPV vaccine was immunogenic and well tolerated. No clinically significant differences were observed between groups. Anti-tetanus antibody kinetics indicated that each of the vaccines could be used for tetanus prophylaxis in acute wound management. For all vaccines, the lowest post-vaccination antibody concentrations were observed in subjects >40 years of age, those seronegative prior to vaccination and those subjects whose last vaccination was ≥20 years ago. In conclusion, dTpa-IPV vaccination of subjects over 14 years of age was as immunogenic and well tolerated as the licensed dTpa
+
IPV or Td-IPV vaccines. Vaccination coverage of adults is poor and the use of combined vaccines such as dTpa-IPV during vaccination visits, or for wound management, maximizes opportunities for boosting in these difficult to reach age groups.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2005.02.013</identifier><identifier>PMID: 15882526</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject><![CDATA[Adolescent ; Adolescents ; Adult ; Age ; Aged ; Aging ; Antibodies, Bacterial - blood ; Antibodies, Viral - blood ; Antigens ; Applied microbiology ; Bacterial diseases ; Biological and medical sciences ; Booster ; Confidence intervals ; Diphtheria ; Diphtheria - prevention & control ; Diphtheria Toxoid - administration & dosage ; Diphtheria Toxoid - adverse effects ; Diphtheria Toxoid - immunology ; Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology ; Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage ; Diphtheria-Tetanus-Pertussis Vaccine - adverse effects ; Diphtheria-Tetanus-Pertussis Vaccine - immunology ; dTpa-IPV ; Ent and stomatologic bacterial diseases ; Female ; France ; Fundamental and applied biological sciences. Psychology ; Germany ; Human bacterial diseases ; Human viral diseases ; Humans ; Immunization, Secondary ; Immunogenicity ; Infectious diseases ; Male ; Medical sciences ; Microbiology ; Middle Aged ; Pertussis Vaccine - administration & dosage ; Pertussis Vaccine - adverse effects ; Pertussis Vaccine - immunology ; Poliomyelitis - prevention & control ; Poliovirus ; Poliovirus Vaccine, Inactivated - administration & dosage ; Poliovirus Vaccine, Inactivated - adverse effects ; Poliovirus Vaccine, Inactivated - immunology ; Prophylaxis ; Public health ; Tetanus ; Tetanus - prevention & control ; Tetanus Toxoid - administration & dosage ; Tetanus Toxoid - adverse effects ; Tetanus Toxoid - immunology ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Combined - administration & dosage ; Vaccines, Combined - adverse effects ; Vaccines, Combined - immunology ; Viral diseases ; Viral diseases of the nervous system ; Whooping Cough - prevention & control]]></subject><ispartof>Vaccine, 2005-05, Vol.23 (28), p.3657-3667</ispartof><rights>2005 Elsevier Ltd</rights><rights>2005 INIST-CNRS</rights><rights>Copyright Elsevier Limited May 25, 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-4fb1841d4f2cf0bb08621f8643eb0bbad6458ce377f8427fd03735cafd2849213</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17163876$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15882526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grimprel, Emmanuel</creatorcontrib><creatorcontrib>von Sonnenburg, Frank</creatorcontrib><creatorcontrib>Sänger, Roland</creatorcontrib><creatorcontrib>Abitbol, Veronique</creatorcontrib><creatorcontrib>Wolter, Joanne M.</creatorcontrib><creatorcontrib>Schuerman, Lode M.</creatorcontrib><title>Combined reduced-antigen-content diphtheria–tetanus–acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Many countries recommend diphtheria, tetanus and/or poliomyelitis boosters in adolescents or adults and the need for pertussis booster vaccination beyond childhood is increasingly recognized. A new combined reduced-antigen-content dTpa-IPV vaccine provides booster vaccination against all four diseases in one single injection. The immunogenicity and safety of the dTpa-IPV vaccine was compared to that of licensed dTpa
+
IPV or Td-IPV vaccines in 806 adolescents >14 years of age and adults with a heterogeneous vaccination history. The dTpa-IPV vaccine was immunogenic and well tolerated. No clinically significant differences were observed between groups. Anti-tetanus antibody kinetics indicated that each of the vaccines could be used for tetanus prophylaxis in acute wound management. For all vaccines, the lowest post-vaccination antibody concentrations were observed in subjects >40 years of age, those seronegative prior to vaccination and those subjects whose last vaccination was ≥20 years ago. In conclusion, dTpa-IPV vaccination of subjects over 14 years of age was as immunogenic and well tolerated as the licensed dTpa
+
IPV or Td-IPV vaccines. Vaccination coverage of adults is poor and the use of combined vaccines such as dTpa-IPV during vaccination visits, or for wound management, maximizes opportunities for boosting in these difficult to reach age groups.</description><subject>Adolescent</subject><subject>Adolescents</subject><subject>Adult</subject><subject>Age</subject><subject>Aged</subject><subject>Aging</subject><subject>Antibodies, Bacterial - blood</subject><subject>Antibodies, Viral - blood</subject><subject>Antigens</subject><subject>Applied microbiology</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Booster</subject><subject>Confidence intervals</subject><subject>Diphtheria</subject><subject>Diphtheria - prevention & control</subject><subject>Diphtheria Toxoid - administration & dosage</subject><subject>Diphtheria Toxoid - adverse effects</subject><subject>Diphtheria Toxoid - immunology</subject><subject>Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - adverse effects</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - immunology</subject><subject>dTpa-IPV</subject><subject>Ent and stomatologic bacterial diseases</subject><subject>Female</subject><subject>France</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Germany</subject><subject>Human bacterial diseases</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunization, Secondary</subject><subject>Immunogenicity</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Pertussis Vaccine - administration & dosage</subject><subject>Pertussis Vaccine - adverse effects</subject><subject>Pertussis Vaccine - immunology</subject><subject>Poliomyelitis - prevention & control</subject><subject>Poliovirus</subject><subject>Poliovirus Vaccine, Inactivated - administration & dosage</subject><subject>Poliovirus Vaccine, Inactivated - adverse effects</subject><subject>Poliovirus Vaccine, Inactivated - immunology</subject><subject>Prophylaxis</subject><subject>Public health</subject><subject>Tetanus</subject><subject>Tetanus - prevention & control</subject><subject>Tetanus Toxoid - administration & dosage</subject><subject>Tetanus Toxoid - adverse effects</subject><subject>Tetanus Toxoid - immunology</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Combined - administration & dosage</subject><subject>Vaccines, Combined - adverse effects</subject><subject>Vaccines, Combined - immunology</subject><subject>Viral diseases</subject><subject>Viral diseases of the nervous system</subject><subject>Whooping Cough - prevention & control</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqFkU2LFDEQhhtR3NnVn6AExEUPPearO5mTyODHwoIeVvEW0knFzdCT9CbpBW-evfoP_SVmmIYFLwsFqSJPvVTV2zTPCF4TTPo3u_WtNsYHWFOMuzWma0zYg2ZFpGAt7Yh82Kww7XnLCf5-0pzmvMMVZGTzuDkhnZS0o_2q-b2N-6GqWJTAzgZsq0PxPyC0JoYCoSDrp-tyDcnrv7_-FCg6zLlm2sA4zqNOaIJU5px9RjpYNMXRR7TMhl7Zq0m3F1--vUYuJjTEmAuk5VsXHwOKDmk7jyU_aR45PWZ4urxnzdcP76-2n9rLzx8vtu8uW8M7WlruBiI5sdxR4_AwYNlT4mTPGQy11LbnnTTAhHCSU-EsZoJ1RjtLJd9Qws6a86PulOLNDLmovc-HbXSAOGfVC0k2mIp7QSIo6xmXFXzxH7iLcwp1CUU6LjCTNSrVHSmTYs4JnJqS3-v0UxGsDp6qnVrupg6eKkxV9bT2PV_U52EP9q5rMbECLxdAZ6NHl3QwPt9xgvRMigP39shBve6th6Sy8RCq6T6BKcpGf88o_wCANcWx</recordid><startdate>20050525</startdate><enddate>20050525</enddate><creator>Grimprel, Emmanuel</creator><creator>von Sonnenburg, Frank</creator><creator>Sänger, Roland</creator><creator>Abitbol, Veronique</creator><creator>Wolter, Joanne M.</creator><creator>Schuerman, Lode M.</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20050525</creationdate><title>Combined reduced-antigen-content diphtheria–tetanus–acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults</title><author>Grimprel, Emmanuel ; von Sonnenburg, Frank ; Sänger, Roland ; Abitbol, Veronique ; Wolter, Joanne M. ; Schuerman, Lode M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-4fb1841d4f2cf0bb08621f8643eb0bbad6458ce377f8427fd03735cafd2849213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adolescent</topic><topic>Adolescents</topic><topic>Adult</topic><topic>Age</topic><topic>Aged</topic><topic>Aging</topic><topic>Antibodies, Bacterial - blood</topic><topic>Antibodies, Viral - blood</topic><topic>Antigens</topic><topic>Applied microbiology</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Booster</topic><topic>Confidence intervals</topic><topic>Diphtheria</topic><topic>Diphtheria - prevention & control</topic><topic>Diphtheria Toxoid - administration & dosage</topic><topic>Diphtheria Toxoid - adverse effects</topic><topic>Diphtheria Toxoid - immunology</topic><topic>Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - adverse effects</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - immunology</topic><topic>dTpa-IPV</topic><topic>Ent and stomatologic bacterial diseases</topic><topic>Female</topic><topic>France</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Germany</topic><topic>Human bacterial diseases</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunization, Secondary</topic><topic>Immunogenicity</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Pertussis Vaccine - administration & dosage</topic><topic>Pertussis Vaccine - adverse effects</topic><topic>Pertussis Vaccine - immunology</topic><topic>Poliomyelitis - prevention & control</topic><topic>Poliovirus</topic><topic>Poliovirus Vaccine, Inactivated - administration & dosage</topic><topic>Poliovirus Vaccine, Inactivated - adverse effects</topic><topic>Poliovirus Vaccine, Inactivated - immunology</topic><topic>Prophylaxis</topic><topic>Public health</topic><topic>Tetanus</topic><topic>Tetanus - prevention & control</topic><topic>Tetanus Toxoid - administration & dosage</topic><topic>Tetanus Toxoid - adverse effects</topic><topic>Tetanus Toxoid - immunology</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Combined - administration & dosage</topic><topic>Vaccines, Combined - adverse effects</topic><topic>Vaccines, Combined - immunology</topic><topic>Viral diseases</topic><topic>Viral diseases of the nervous system</topic><topic>Whooping Cough - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grimprel, Emmanuel</creatorcontrib><creatorcontrib>von Sonnenburg, Frank</creatorcontrib><creatorcontrib>Sänger, Roland</creatorcontrib><creatorcontrib>Abitbol, Veronique</creatorcontrib><creatorcontrib>Wolter, Joanne M.</creatorcontrib><creatorcontrib>Schuerman, Lode M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Health Management Database (Proquest)</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grimprel, Emmanuel</au><au>von Sonnenburg, Frank</au><au>Sänger, Roland</au><au>Abitbol, Veronique</au><au>Wolter, Joanne M.</au><au>Schuerman, Lode M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combined reduced-antigen-content diphtheria–tetanus–acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2005-05-25</date><risdate>2005</risdate><volume>23</volume><issue>28</issue><spage>3657</spage><epage>3667</epage><pages>3657-3667</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Many countries recommend diphtheria, tetanus and/or poliomyelitis boosters in adolescents or adults and the need for pertussis booster vaccination beyond childhood is increasingly recognized. A new combined reduced-antigen-content dTpa-IPV vaccine provides booster vaccination against all four diseases in one single injection. The immunogenicity and safety of the dTpa-IPV vaccine was compared to that of licensed dTpa
+
IPV or Td-IPV vaccines in 806 adolescents >14 years of age and adults with a heterogeneous vaccination history. The dTpa-IPV vaccine was immunogenic and well tolerated. No clinically significant differences were observed between groups. Anti-tetanus antibody kinetics indicated that each of the vaccines could be used for tetanus prophylaxis in acute wound management. For all vaccines, the lowest post-vaccination antibody concentrations were observed in subjects >40 years of age, those seronegative prior to vaccination and those subjects whose last vaccination was ≥20 years ago. In conclusion, dTpa-IPV vaccination of subjects over 14 years of age was as immunogenic and well tolerated as the licensed dTpa
+
IPV or Td-IPV vaccines. Vaccination coverage of adults is poor and the use of combined vaccines such as dTpa-IPV during vaccination visits, or for wound management, maximizes opportunities for boosting in these difficult to reach age groups.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15882526</pmid><doi>10.1016/j.vaccine.2005.02.013</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2005-05, Vol.23 (28), p.3657-3667 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67819027 |
| source | ScienceDirect Journals |
| subjects | Adolescent Adolescents Adult Age Aged Aging Antibodies, Bacterial - blood Antibodies, Viral - blood Antigens Applied microbiology Bacterial diseases Biological and medical sciences Booster Confidence intervals Diphtheria Diphtheria - prevention & control Diphtheria Toxoid - administration & dosage Diphtheria Toxoid - adverse effects Diphtheria Toxoid - immunology Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage Diphtheria-Tetanus-Pertussis Vaccine - adverse effects Diphtheria-Tetanus-Pertussis Vaccine - immunology dTpa-IPV Ent and stomatologic bacterial diseases Female France Fundamental and applied biological sciences. Psychology Germany Human bacterial diseases Human viral diseases Humans Immunization, Secondary Immunogenicity Infectious diseases Male Medical sciences Microbiology Middle Aged Pertussis Vaccine - administration & dosage Pertussis Vaccine - adverse effects Pertussis Vaccine - immunology Poliomyelitis - prevention & control Poliovirus Poliovirus Vaccine, Inactivated - administration & dosage Poliovirus Vaccine, Inactivated - adverse effects Poliovirus Vaccine, Inactivated - immunology Prophylaxis Public health Tetanus Tetanus - prevention & control Tetanus Toxoid - administration & dosage Tetanus Toxoid - adverse effects Tetanus Toxoid - immunology Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, Combined - administration & dosage Vaccines, Combined - adverse effects Vaccines, Combined - immunology Viral diseases Viral diseases of the nervous system Whooping Cough - prevention & control |
| title | Combined reduced-antigen-content diphtheria–tetanus–acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T23%3A55%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combined%20reduced-antigen-content%20diphtheria%E2%80%93tetanus%E2%80%93acellular%20pertussis%20and%20polio%20vaccine%20(dTpa-IPV)%20for%20booster%20vaccination%20of%20adults&rft.jtitle=Vaccine&rft.au=Grimprel,%20Emmanuel&rft.date=2005-05-25&rft.volume=23&rft.issue=28&rft.spage=3657&rft.epage=3667&rft.pages=3657-3667&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2005.02.013&rft_dat=%3Cproquest_cross%3E3379187191%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c452t-4fb1841d4f2cf0bb08621f8643eb0bbad6458ce377f8427fd03735cafd2849213%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1547038038&rft_id=info:pmid/15882526&rfr_iscdi=true |